Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 9:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,099 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bioavailability Study Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fasting Conditions

NCT00759759
View directory record Official record
Conditions
Healthy
Interventions
morphine sulfate sustained-release capsules, KADIAN (morphine sulfate sustained-release) capsules
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 27, 2026, 9:26 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Food on the Oral Bioavailability of AEF0117 in Healthy Volunteers

NCT05451017
View directory record Official record
Conditions
Marijuana Abuse
Interventions
3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fed condition, 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fasting condition
Drug
Lead sponsor
Aelis Farma
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 27, 2026, 9:26 AM EDT
Completed Phase 1 Interventional

To Compare Relative Bioavailability of Two Clinical Formulations of Linifanib.

NCT01381341
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
linifanib
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Oct 27, 2026, 9:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948

NCT06691828
View directory record Official record
Conditions
Healthy Volunteer
Interventions
NX-5948
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 27, 2026, 9:26 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Fluoride in Saliva After Use of Fluoride Toothpastes Followed by Fluoride Mouthrinses

NCT05601154
View directory record Official record
Conditions
Dental Caries
Interventions
Crest Cavity Protection toothpaste, Crest Cavity Protection toothpaste followed by Act Mint Fluoride Rinse, Colgate PreviDent 5000+ toothpaste, Colgate PreviDent 5000+ toothpaste followed by Act Mint Fluoride Rinse
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 27, 2026, 9:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

15 mg Mirtazapine Orally Disintegrating Tablets, Fasting

NCT00835575
View directory record Official record
Conditions
Healthy
Interventions
Mirtazapine 15 mg (Orally Disintegrating) Tablets, REMERON SolTab® 15 mg Orally Disintegrating Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 27, 2026, 9:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

This Is A Study Of Bioavailability And Food Effect For Fesoterodine.

NCT01286454
View directory record Official record
Conditions
Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency
Interventions
fesoterodine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 26, 2012 · Synced Oct 27, 2026, 9:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Divalproex Sodium Delayed-Release Tablets Under Fasting Conditions

NCT00834639
View directory record Official record
Conditions
Healthy
Interventions
divalproex sodium, Depakote®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2009 · Synced Oct 27, 2026, 9:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fast & Fed Pharmacokinetic (PK) Study

NCT00692016
View directory record Official record
Conditions
Bioavailability
Interventions
Naproxen sodium
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 27, 2026, 9:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects

NCT02034591
View directory record Official record
Conditions
Healthy Subjects
Interventions
Apixaban, Boost Plus
Drug · Dietary Supplement
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Oct 27, 2026, 9:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects

NCT02648438
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
AZD7594 Solution for infusion (150 μg intravenous formulation), AZD7594 Oral suspension (1200 μg oral formulation), AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler), AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler), AZD7594 Pressurized inhalation suspension (400 μg) by pMDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 27, 2026, 9:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435

NCT01209117
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae, Infection, Human Immunodeficiency Virus
Interventions
GSK2248761 WBM Capsule, GSK2248761 WBM Tablet Formulation 1, GSK2248761 WBM Tablet Formulation 2, GSK2248761 WBM Tablet Formulation 3, GSK2248761 WBM Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 27, 2026, 9:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Tolerability, and Bioavailability of Orally Administered Venglustat in Healthy Adult Participants

NCT06418620
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Venglustat
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 45 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 27, 2026, 9:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting

NCT00835549
View directory record Official record
Conditions
Healthy
Interventions
Cefdinir for oral suspension 250 mg/5mL, OMNICEF® for oral suspension 250 mg/5mL
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 27, 2026, 9:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate

NCT00876655
View directory record Official record
Conditions
Healthy
Interventions
TR-701 di-sodium phosphate salt, TR-701 free acid phosphate
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 27, 2026, 9:26 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Testing the Bioavailability of Phytonutrients, Curcumin and Ursolic Acid

NCT04421716
View directory record Official record
Conditions
Bioavailability of Phytonutrients
Interventions
Ursolic Acid, Curcumin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 27, 2026, 9:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants

NCT05136404
View directory record Official record
Conditions
Healthy
Interventions
Selpercatinib
Drug
Lead sponsor
Loxo Oncology, Inc.
Industry
Eligibility
21 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 27, 2026, 9:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Calcium Absorption in Postmenopausal Thai Women

NCT02291315
View directory record Official record
Conditions
Fractional Calcium Absorption
Interventions
Not listed
Lead sponsor
Cornell University
Other
Eligibility
53 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2014 · Synced Oct 27, 2026, 9:26 AM EDT
Completed Phase 1 Interventional

Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations

NCT07226778
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Maridebart Cafraglutide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Anaheim, California • Daytona Beach, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 27, 2026, 9:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride

NCT00400335
View directory record Official record
Conditions
Hypogonadism, Hypogonadism, Male
Interventions
Nanomilled testosterone, commercially available dutasteride, Nanomilled dutasteride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 27, 2026, 9:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants

NCT04991571
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Zibotentan (Treatment A), Dapagliflozin (Treatment A), Zibotentan/Dapagliflozin - Formulation 1 (Treatment B), Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 27, 2026, 9:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation

NCT01484964
View directory record Official record
Conditions
Pharmacokinetics of ASP015K, Bioavailability of ASP015K, Healthy Subjects
Interventions
ASP015K
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2011 · Synced Oct 27, 2026, 9:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

NCT02738931
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir 50 mg tablet, Lamivudine 300 mg tablet, Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA), Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 27, 2026, 9:26 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid

NCT06916143
View directory record Official record
Conditions
Healthy Participants
Interventions
LY4100511, Rabeprazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Miami, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 27, 2026, 9:26 AM EDT